The prevalence of ESBL among enterobacteriaceae in a tertiary care hospital of North Karnataka, India

Journal of Clinical and Diagnostic Research

Volumn 5, Issue 3, 2011, Pages 470-475

  Metri Basavaraj, C ^a   Jyothi, P ^a   Peerapur Basavaraj, V ^a  

^a BLDE UNIVERSITY   (India)

Author keywords

Double disc synergy test; Enterobacteriaceae; Extended spectrum lactamases; Phenotypic disc confirmatory test

Indexed keywords

AMIKACIN; AMPICILLIN; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; CLAVULANIC ACID; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; GATIFLOXACIN; GENTAMICIN; IMIPENEM; NALIDIXIC ACID; NITROFURANTOIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CITROBACTER; CONTROLLED STUDY; DISK DIFFUSION; DOUBLE DISK SYNERGY TEST; ENTEROBACTERIACEAE; ENZYME ANALYSIS; ENZYME SYNTHESIS; ESCHERICHIA COLI; FEMALE; HUMAN; INDIA; INFANT; KLEBSIELLA PNEUMONIAE; MALE; NONHUMAN; PHENOTYPIC DISK CONFIRMATORY TEST; PROTEUS; TERTIARY HEALTH CARE;

ENTEROBACTERIACEAE;

EID: 79959286485     PISSN: None     EISSN: 0973709X     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Greenwood D. Resistance to antimicrobial agents: a personal view. J Med Microbiol 1998; 47: 751-5.
2. Rossolini GM, Mantengoli E. Antimicrobial resistance in Europe and its potential impact on empirical therapy. Clin Microbiol Infect 2008; 14 (6): 2-8.
3. Thomson KS. Controversies about extended-spectrum and AmpC ß-lactamases. Emerg Infect Dis 2001;7:333-6.
4. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for ß-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211-33.
5. Kiratisin P, Apisarnthanarak A, Laesripa C, and Saifon P. Molecular characterization and epidemiology of extended-spectrum ß-lactamaseproducing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic. Antimicrob Agents Chemother 2008;52(8):2818-24.
6. Chaudhary U, Aggarwal R. Extended spectrum ß-lactamases (ESBL) - An emerging threat to clinical therapeutics. Indian J Med Microbiol 2004;22(2): 75-80.
7. Nathisuwan S, Burgess DS, Lewis JS. Extended-spectrum ß-lactamases: epidemiology, detection, and treatment. Pharmacotherapy 2001; 21:920-8.
8. Palucha A, Mikiewiez B, Hryniewiez W, Griadkowski M. Concurrent outbreaks of extended-spectrum ß-lactamase producing organisms of the family Enterobacteriaceae in a Warsaw Hospital. J Antimicrob Chemother 1999;44:489-499.
9. Luzzaro F, Mezzatesta M, Mugnaioli C, Perilli M, Stefani S,Amicosante G,Rossolini GM, Toniolo A. Extended-Spectrum ß-lactamases among enterobacteria of Medical Interest: Report of the Second Italian Nationwide Survey. J Clin Microbiol 2006; 44(5):1659-1664.
10. Khan MKR, Thukral SS, Gaind R. Evaluation of a modified doubledisc synergy test for detection of extended-spectrum ß-lactamases in AMPC ß-lactamase-producing Proteus mirabilis, Indian J Med Microbiol 2008;26(1): 58-61.
11. Bhattacharjee A, Sen MR, Prakash P, Gaur A, Anupurba S. Increased prevalence of extended-spectrum ß lactamase producers in neonatal septicaemic cases at a tertiary referral hospital. Indian J Med Microbiol 2008;26(4): 356-60.
12. Menon T, Bindu D, Kumar CPG, Nalini S, Thirunarayan MA. Comparison of double disc and three dimensional methods to screen for ESBL producers in a tertiary care hospital. Indian J Pathol Microbiol 2006;24(2): 117-120.
13. Babypadmini S, Appalaraju B. Extended -spectrum ß-lactamases in urinary isolates of Escherichia coli and Klebsiella pneumoniae - Prevalence and susceptibility pattern in a tertiary care hospital. Indian J Med Microbiol 2004;22(3):172-174.
14. Shanmuganathan C, Ananthakrishnan A, Jayakeerthi SR, Kanungo R, Kumar A, Bhattacharya S,Badrinath S. Learning from an outbreak: ESBL- the essential points. Indian J Med Microbiol 2004;22(4): 255-257.
15. Rodrigues C, Joshi P, Jani SH, Alphonse M, Radhakrishnan R, Mehta A. Detection of ß-Lactamases in nosocomial Gram negative clinical isolates. Indian J Med Microbiol 2004;22(4): 247-250.
16. Shukla I, Tiwari R, Agarwal M. Prevalence of Extended spectrum ß-lactamase producing Klebsiella pneumoniae in a tertiary care hospital. Indian J Med Microbiology.(2004);22 (2): 87-91.
17. Vinodkumar CS, Neelagund YF. Extended-spectrum ß-lactamase mediated resistance to third generation cephalosporins among Klebsiella pneumoniae in neonatal septicemia. J Indian Paediatr; 2004: 41: 97-99
18. Krishnan PU and Macaden R. Spread of multidrug resistant Klebsiella pneumoniae in a tertiary care hospital. Abstracted in the proceedings of the 4th International conference of the hospital infection society, Edinburgh, Sept 1998;676.
19. Krishna BVS, Patil AB, Chandrasekhar MR. Extended-spectrum ß-lactamase Producing Klebsiella pneumoniae in Neonatal Intensive Care Unit. Indian J Pediatr 2007; 74 (7): 627-630.
20. Sridhar Rao PN, Basavarajappa KG, Krishna GL. Detection of extended-spectrum ß-lactamase from clinical isolates in Davangere. Indian J Pathol Microbiol 2008;51(4):497-9.
21. Paterson DL, Ko WC, Gottberg AV, Casellas JM, Mulazimoglu L, Klugman KP, Bonomo RA, Rice LB, McCormack JG, Yu VL. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum ß-lactamases: Implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39(6): 2206-2212.
22. Sanders CC, Sanders WE, Molandes ES. Characterization of ß-lactamases in situ on polyacrylamide gels. Antimicrob Agents Chemother 1986;30(6):951-52.
23. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing; Eighth informational supplement. M100-S8. NCCLS, Wayne, PA;1998;7767
24. Clinical and Laboratory Standards Institute. 2005 guidelines by CLSI/ NCCLS - CLSI informational supplement. Approved standard M100- S15 Wayne, PA; 2000;565
25. Jarlier V, Nicolas M, Fournier G, Philippon A. Extended spectrum ß-lactamases conferring transferable resistance to newer ß-lactam agents in Enterobacteriaceae: Hospital prevalence and susceptibility patterns. Rev Infect Dis 1988;10:867-78.
26. Mathur P, Kapil A, Das B, Dhawan B. Prevalence of extendedspectrum ß- lactamase producing Gram negative bacteria in tertiary care hosptital. Indian J Med Res 2002;115:153-157.
27. Wattal C, Sharma A, Oberoi JK, Datta S, Prasad KJ, Raveendr R. ESBL- An emerging threat to antimicrobial therapy. Microbiology Newsletter 2005. Sir Ganga Ram Hospital, Vol 10, No 1. 1-8.
28. Subha A, Ananthan S. Extended-Spectrum ß-lactamase (ESBL) mediated resistance to third generation cephalosporins among Klebsiella pneumoniae in Chennai. Indian J Med Microbiol 2002;20:92-5.
29. Jain A, Roy I, Gupta MK, Kumar M, Agarwal SK. Prevalence of extended-spectrum ß-lactamase-producing Gram-negative bacteria in septicemic neonates in a tertiary care hospital. J Med Microbiol 2003;52:421-5.
30. Gangone PJ, Bedenic B, Koulla SS, Randegger C, Adiogod D, Petal N. Extended-spectrum ß-lactamase-producing Enterobacteriaceae in Yaounde,Cameroon. J Clin Microbiol 2005;43(7):3273-7.
31. Gotale M, Manthalkar P, Kandle S, Yamul V, Jahagirdhar V. Co-relation of extended-spectrum ß-lactamase-production with cephalosporins resistance in Gram negative bacilli. Indian J Pathol Microbiol 2004;47(1): 82-84.
32. Bell JM, Turnidge JD, Jones RN. Prevalence of extended-spectrum ß-lactamase-producing Enterobactor cloacae in the Asia -pacific region; Results for the SENTRY antimicrobial surveillance program, 1998 to 2001. Antimicrob Agents Chemother 2003;47(12): 3989-93.
33. Sahm F D, Thornsberry C, Mayfield DC, Jones ME, Karlowsky JA. Multidrug-resistant urinary tract isolates of Escherichia coli: prevalence and patient demographics in the United States in 2000. Antimicrob Agents Chemother 2001;Vol 45(5): 1402-06.